This biotech giant could see significant profit growth in the coming years. The post Here's the earnings forecast out to 2029 for CSL shares appeared first on The Motley Fool Australia.

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

Haemonetics Corporation HAE delivered third-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.19, which rose 14.4% ...

The even better news is that the general consensus is that CSL stock could generate big returns over the next 12 months. Let's look at what a few brokers are saying about the plasma therapies leader.

Roughly 3% of eligible people donate blood each year ... There are red blood cells, plasma and platelets that can be separated out of whole blood to be given to patients as needed.

It said: The last five years have been particularly challenging for CSL, with the business navigating material inflationary pressures to its plasma collections costs, the threat of a new entrant ...

Bills fans showed love to Mark Andrews last week, and now Ravens supporters are returning the favor. After Andrews' fourth quarter fumble and dropped two-point conversion attempt helped the Bills ...

These bank stocks are all $50 billion or more in market value with a 3% yield or higher.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

The money will go towards organizations like the ... The 12 pro sports teams in Los Angeles are coming together to donate more than $8 million to support victims of fires pic.twitter.com ...